NASDAQ
MORF

Morphic Holding Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Morphic Holding Inc Stock Price

Vitals

Today's Low:
$53.98
Today's High:
$55.38
Open Price:
$53.98
52W Low:
$23.03
52W High:
$63.083
Prev. Close:
$54.21
Volume:
485670

Company Statistics

Market Cap.:
$2.68 billion
Book Value:
15.232
Revenue TTM:
$8.71 million
Operating Margin TTM:
-1636.79%
Gross Profit TTM:
$-31254000
Profit Margin:
0%
Return on Assets TTM:
-15.33%
Return on Equity TTM:
-23.19%

Company Profile

Morphic Holding Inc had its IPO on 2019-06-27 under the ticker symbol MORF.

The company operates in the Healthcare sector and Biotechnology industry. Morphic Holding Inc has a staff strength of 110 employees.

Stock update

Shares of Morphic Holding Inc opened at $53.98 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $53.98 - $55.38, and closed at $54.75.

This is a +1% increase from the previous day's closing price.

A total volume of 485,670 shares were traded at the close of the day’s session.

In the last one week, shares of Morphic Holding Inc have slipped by -2.07%.

Morphic Holding Inc's Key Ratios

Morphic Holding Inc has a market cap of $2.68 billion, indicating a price to book ratio of 2.901 and a price to sales ratio of 14.0334.

In the last 12-months Morphic Holding Inc’s revenue was $8.71 million with a gross profit of $-31254000 and an EBITDA of $-141562000. The EBITDA ratio measures Morphic Holding Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Morphic Holding Inc’s operating margin was -1636.79% while its return on assets stood at -15.33% with a return of equity of -23.19%.

In Q2, Morphic Holding Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 78.1%.

Morphic Holding Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-3.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Morphic Holding Inc’s profitability.

Morphic Holding Inc stock is trading at a EV to sales ratio of 9.3154 and a EV to EBITDA ratio of -12.0627. Its price to sales ratio in the trailing 12-months stood at 14.0334.

Morphic Holding Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$748.72 million
Total Liabilities
$17.81 million
Operating Cash Flow
$0
Capital Expenditure
$293000
Dividend Payout Ratio
0%

Morphic Holding Inc ended 2024 with $748.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $748.72 million while shareholder equity stood at $729.36 million.

Morphic Holding Inc ended 2024 with $0 in deferred long-term liabilities, $17.81 million in other current liabilities, 5000.00 in common stock, $-372243000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $217.28 million and cash and short-term investments were $731.36 million. The company’s total short-term debt was $1,560,000 while long-term debt stood at $0.

Morphic Holding Inc’s total current assets stands at $742.62 million while long-term investments were $0 and short-term investments were $514.08 million. Its net receivables were $0.00 compared to accounts payable of $3.66 million and inventory worth $0.

In 2024, Morphic Holding Inc's operating cash flow was $0 while its capital expenditure stood at $293000.

Comparatively, Morphic Holding Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$54.75
52-Week High
$63.083
52-Week Low
$23.03
Analyst Target Price
$74

Morphic Holding Inc stock is currently trading at $54.75 per share. It touched a 52-week high of $63.083 and a 52-week low of $63.083. Analysts tracking the stock have a 12-month average target price of $74.

Its 50-day moving average was $55.75 and 200-day moving average was $45.02 The short ratio stood at 6.76 indicating a short percent outstanding of 0%.

Around 1664% of the company’s stock are held by insiders while 7302.8% are held by institutions.

Frequently Asked Questions About Morphic Holding Inc

The stock symbol (also called stock or share ticker) of Morphic Holding Inc is MORF

The IPO of Morphic Holding Inc took place on 2019-06-27

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$10.7
0.02
+0.19%
$13.4
0.07
+0.53%
$37.7
0.73
+1.97%
$1300.7
-41.6
-3.1%
$9.54
-0.08
-0.83%
$3.62
-0.01
-0.28%
$143.33
2.53
+1.8%
$17.39
0.78
+4.7%
$271.2
-14.5
-5.08%
$0.79
0.01
+1.65%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company’s products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children’s Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Address

35 Gatehouse Drive, A2, Waltham, MA, United States, 02451